Who makes [Part 1.1] IDG-16177?

[Part 1.1] IDG-16177 is developed by IlDong Pharmaceutical Co Ltd.

What development phase is [Part 1.1] IDG-16177 in?

[Part 1.1] IDG-16177 is in Phase 1.

Last reviewed 2026-04-19 · How we verify

[Part 1.1] IDG-16177

IlDong Pharmaceutical Co Ltd · Phase 1 active Small molecule

At a glance

Generic name	[Part 1.1] IDG-16177
Sponsor	IlDong Pharmaceutical Co Ltd
Modality	Small molecule
Phase	Phase 1

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

[Part 1.1] IDG-16177 CI brief — competitive landscape report
[Part 1.1] IDG-16177 updates RSS · CI watch RSS
IlDong Pharmaceutical Co Ltd portfolio CI